Narcolepsy, a chronic neurological disorder, significantly impacts the daily lives of those affected due to excessive daytime sleepiness (EDS). Modafinil has been a cornerstone in managing EDS, but its effectiveness can wane over time due to tolerance. An innovative approach, using the drug pitolisant during modafinil ‘drug holidays’, offers new hope for resetting tolerance and …
Recent advancements in neuropharmacology have brought to light S-CE-123, a dopamine transporter inhibitor showing remarkable promise in cognitive enhancement. Its emergence alongside R-modafinil, a well-studied compound with a similar target, paves the way for a fascinating comparative study. This duo of compounds, entwined in the complex dance of brain chemistry, offers a glimpse into the …
In the pursuit of peak mental performance, scientific studies have explored the effects of stimulants like methylphenidate, modafinil, and caffeine on cognitive functions such as memory and attention. Recent research utilizing advanced neuroimaging techniques has begun to unravel the intricate ways these substances modulate brain activity and connectivity, offering insights into their potential as cognitive …
Modafinil (brand name “Provigil”) is a blockbuster eugeroic drug synthesized by Cephalon Pharmaceuticals (now Teva) and approved in 1998 for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy. It was since approved for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea, as well as to normalize circadian rhythms in diagnoses …
Hydrafinil (Fluorenol) is an unregulated research chemical originally synthesized by Cephalon Pharmaceuticals (now owned by Teva) as a eugeroic (wakefulness-promoting agent). After its synthesis, fluorenol was one of several agents to be considered as a hypothetical successor to the popularized and FDA-approved drug, Provigil (Modafinil). Comparative data from animal trials indicated that fluorenol exhibited ~39% …
Provigil (Modafinil) is a eugeroic drug that was originally approved in 1998 for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Despite never attaining FDA approval for the treatment of depression, many anecdotal reports highlight the efficacy of Provigil as an antidepressant. The drug tends to …
Provigil (modafinil) is a drug that was approved in 1998 for the treatment of excessive daytime sleepiness associated with narcolepsy. It has since been granted FDA approval for the treatment of obstructive sleep apnea as well as shift work sleep disorder. Adderall (mixed amphetamine salts) is a psychostimulant drug that was initially approved in 1996 …